Some possible molecular mechanisms of VEGF encoding plasmids functioning



Citar

Texto integral

Resumo

Gene therapeutic approaches to the restoration of the
ischemic tissue perfusion are considered very promising,
but to this time the molecular mechanisms which allow the
therapeutic gene encoding plasmid to transfect the target
cell and underlie the positive clinical effects remain unknown.
In this review the possible molecular mechanisms of the
angiogenic factor VEGF encoding plasmid penetration into the
cytoplasm and the nucleus of the target cell are discussed,
and also the methods for better transfection and the gene of
interest expression are proposed.

Sobre autores

A Grigorian,

Human Stem Cells Institute, Moscow

Human Stem Cells Institute, Moscow

K Schevchenko

Human Stem Cells Institute, Moscow

Human Stem Cells Institute, Moscow

Bibliografia

  1. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nature Medicine 2003; 9: 669-76.
  2. Ferraro B., Cruz Y.L., Baldwin M., Coppola D., Heller R. Increased perfusion and angiogenesis in a hindlimb ischemia model with plasmid FGF-2 delivered by noninvasive electroporation. Gene Therapy 2010; 17: 763-9.
  3. Nikol S. Viral or non-viral angiogenesis gene transfer - New answers to old questions. Cardiovasc. Res. 2007; 73: 443-5.
  4. Sylven C. Angiogenic gene therapy. Drugs of today 2002; 38: 819-27.
  5. Деев Р.В., Григорян А.С., Потапов И.В. и др. Мировой опыт и тенденции генной терапии ишемических заболеваний. Ангиология и сосуд. хирургия 2011; 17 (2): 145-54.
  6. Wiley Gene Therapy Clinical Trials Worldwide. http://www.wiley. com/legacy/wileychi/genmed/clinical/
  7. Douglas J. Adenoviral vectors for gene therapy. Mol. Biotechnol. 2007; 36 (1): 71-80.
  8. Yang Y., Wilson J.M. Clearance of adenovirus-infected hepatocytes by MHC class I restricted CD4+ CTLs in vivo. J. Immunol. 1995; 155: 2564-9.
  9. Melillo G., Scoccianti M., Kovesdi I. et al. Gene therapy for collateral vessel development. Cardiovasc. Res. 1997; 35: 480-9.
  10. Williams P.D., Ranjzad P., Kakar S.J. Development of viral vectors for use in cardiovascular gene therapy. Viruses 2010; 2: 334-71.
  11. Harris J.D., Lemoine N.R. Strategies for targeted gene therapy. Trends Genet. 1996; 12: 400-5.
  12. Sinn P.L., Sauter S.L., McCray P.B. Lipoplex size is a major determinant of in vitro lipofection efficiency. Gene Therapy 2005; 12: 1089-98.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Eco-Vector, 2011



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies